A recent report published by Infinium Global Research on alzheimer’s drugs market provides an in-depth analysis of segments and sub-segments in global as well as regional alzheimer’s drugs market. The study also highlights the impact of drivers, restraints and macro indicators on the global and regional alzheimer’s drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global alzheimer’s drugs market. According to the report, the global alzheimer’s drugs market is projected to grow at a CAGR of 7.0% over the forecast period of 2018-2024.
Alzheimer's disease is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. Cholinesterase inhibitors are set to treat symptoms related to memory, language, thinking, judgment and other thought processes. Alzheimer's drugs prevent the breakdown of a chemical messenger in the brain. It is the cause of 60–70% of cases of dementia.
The cholinergic, memantine, combined drug, and other drugs are used to treat alzheimer's disease. The presence of high revenue-generating drugs such as Donepezil, Exelon, and galantamine is a key driver, for the growth of cholinergic drug. Memantine, the fifth alzheimer's drug, is an NMDA (N-methyl-D-aspartate) receptor antagonist has dominated the drug class segment due to a large number of patent expiry of major products and a restricted number of drugs to treat alzheimer's disease.
The rising occurrence of neurodegenerative diseases among the elderly and healthy support from governments across developed countries have led to the development of new drugs and therapies which have helped in the development and growth of the alzheimer’s drugs market. Additionally, lack of Duchenne muscular dystrophy (DMD) is another factor that promotes the growth of the market. The lack of DMDs extends the treatment schedule for alzheimer's disease, which in turn, increases the healthcare costs for patients.
Among the regions, North America is expected to the largest market for alzheimer's drugs. A large number of patients suffering from alzheimer's disease, high purchasing power for expensive drugs and compensation policies for the treatment of this disease is likely to boost the growth in this market. The increasing awareness about neurodegenerative diseases in the Asia-Pacific region will boost the growth of the global alzheimer’s drugs market in the next coming years.
The report on global alzheimer’s drugs market covers segments such as drug class and distribution channel. On the basis of drug class, the global alzheimer’s drugs market is categorized into cholinergic, memantine, combined drug and others. On the basis of the distribution channel, the global alzheimer’s drugs market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography are provided over the period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain and Rest of Europe are included in the European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-Pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience a growth at a CAGR of x.x% over the period of -.
The report provides profiles of the companies in the global alzheimer’s drugs market such as H Lundbeck A/S, Eisai Co Ltd, Ono Pharmaceutical, Daiichi Sankyo Company Limited, Johnson & Johnson, Merz Holding GmbH & Co KG and Others.
The report provides deep insights on demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the global alzheimer’s drugs market. Moreover, IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of alzheimer’s drugs market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the alzheimer’s drugs market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. This report will help manufacturers, suppliers, and distributors of alzheimer’s drugs market to understand the present and future trends in this market and formulate their strategies accordingly.
Get free analyst support for the queries before and post purchasing report.
Be assured of 100% customer satisfaction about the research and get 24X7 customer support.
Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.
sign up for our newsletter